Navigation Links
Metamark Genetics Signs Collaboration Agreement on Novel Therapeutic Targets with Janssen Biotech
Date:12/19/2011

CAMBRIDGE, Mass., Dec. 19, 2011 /PRNewswire/ -- Metamark Genetics, Inc. announced today that it has entered into a research, collaboration, and license agreement with Janssen Biotech, Inc.  The agreement is based on Metamark's discovery platform for the identification and characterization of specific proprietary cancer targets demonstrated to play a causal role in promoting tumor progression and spread (Prognosis Determinants™). The collaboration will focus on the evaluation and validation of several of Metamark's Prognosis Determinants. Upon selection of the targets, Janssen Biotech will receive a limited exclusive license under Metamark's intellectual property and know-how and will thereafter be responsible for the discovery, development, and commercialization of therapeutic inhibitors targeting the specific Prognosis Determinants.

 "We are delighted to enter into this important alliance with Janssen Biotech," said Eric Devroe, Ph.D., Vice President of Business & Strategy Development at Metamark. "This collaboration and license agreement reflects the value of Metamark's innovative approach to identifying genes and proteins that drive aggressive behavior of tumors – both in the development of prognostic assays as well as in supporting the discovery and development of novel targeted therapeutics."

Metamark will receive an initial upfront payment from Janssen Biotech as well as near-term milestone payments following initial target validation. Under the terms of the agreement, Metamark may be eligible to receive up to $365 million in milestone payments across multiple targets, based upon the achievement of specified development, regulatory, and commercialization goals. In addition, Metamark will be entitled to royalties on worldwide net sales of therapeutics and any associated companion diagnostics upon commercialization.

Commenting on the agreement, Metamark President and CEO, Mark R. Straley, stated, "Our ultimate mission at Metamark Genetics is to improve cancer patient outcomes by empowering personalized treatment decisions.  This collaboration advances our mission by enabling us to apply our unique understanding of tumor biology to direct the discovery and development of tumor-specific drugs and compounds."

About Metamark Genetics, Inc.
Metamark is a privately held oncology company focused on the development of function-based prognostic assays for early staged cancers. The MetamarkDx™ Prognostic Assays under development are based on Metamark's proprietary Prognosis Determinants™, genes discovered through leading edge cancer research and demonstrated to play a causal role in promoting tumor progression and spread. For further information, please visit the company's website at www.metamarkgenetics.com.

Cautionary Note Regarding Forward-Looking Statements

This press release, and information contained on Metamark's website, contains forward-looking statements that involve substantial risks and uncertainties, including statements regarding Metamark's strategies and future plans, prospects and results, are forward-looking statements. The words "anticipate," "believe," "expect," "intend," "may," "plan," and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.   Metamark may not actually achieve the plans or expectations disclosed in its forward-looking statements, and you should not place undue reliance on its forward-looking statements.  

 

 

 

 


'/>"/>
SOURCE Metamark Genetics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Metamark Genetics, Inc. Announces New Chief Scientific Officer
2. Metamark Genetics, Inc. Announces New Chief Executive Officer
3. Metamark and HistoRx Announce Licensing Agreement for AQUA® Technology
4. Interleukin Genetics Licenses its PST(R) Genetic Test to OralDNA Labs
5. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Healthcare Conference 2008
6. Interleukin Genetics and Alticor Agree on Expansion of Distribution Channels for Genetic Tests
7. Expression Genetics EGEN-001 Named One of 10 Most Promising Oncology Products by Windhover
8. Exosome Diagnostics Appoints Johan Skog, Ph.D., as Director of Genetics Research
9. MedImmune Licenses Reverse Genetics Technology to Hungarys Omninvest for Use in Influenza Vaccine Development and Production
10. deCODE genetics Announces Webcast of Conference Call to Discuss Third Quarter 2008 Financial Results
11. Interleukin Genetics to Present New Findings at the 11th Cardiovascular Genomics and Atherosclerosis Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... February 08, 2016 , ... Bulk food ... bulk foods at various stages of the production process. Despite frequently inspecting loose ... bulk products post packaging such as sacks of dry powders. , Mettler-Toledo Product ...
(Date:2/8/2016)... 2016 --> ... "Company"), the ultra-rapid Point-Of-Care (POC) molecular diagnostics company, today announces ... trachomatis (CT) test to be launched on the Company,s io® ... the CT test is now cleared for sale within the ... The launch of the io® CT test signals a new ...
(Date:2/5/2016)... Feb. 5, 2016 On Thursday, February 11, ... source for community, health and disaster services, and the ... integrate to enhance care coordination and service delivery for ... they need and to better connect service providers to ... San Diego has handled more ...
(Date:2/4/2016)... Feb. 4, 2016  Sangamo BioSciences, Inc. (NASDAQ: ... today that Edward Lanphier , Sangamo,s president and ... progress of Sangamo,s ZFP Therapeutic ® development programs ... 2:40 pm ET on Thursday, February 11, 2016, at ... Conference. The conference is being held in ...
Breaking Biology Technology:
(Date:2/3/2016)... 2016 Vigilant Solutions announces today that the ... Missouri solved two recent hit-and-run cases ... from Vigilant Solutions. Brian Wenberg explains, ... victim was walking out of a convenience store and witnessed an elderly male ... vehicle, striking his vehicle and leaving the scene.  In ...
(Date:2/2/2016)... NEW YORK , Feb. 2, 2016 ... healthcare facilities are primarily focused on medical ... that measure point-of-care parameters. Wearable devices that ... a user,s freedom of movement are being ... sensors for human biomedical signal acquisition coupled ...
(Date:2/2/2016)... 2016 Checkpoint Inhibitors for Cancer – ... Are you interested in the future of cancer ... inhibitors. Visiongain,s report gives those predictions to 2026 ... level. Avoid falling behind in data or ... revenues those emerging cancer therapies can achieve. There ...
Breaking Biology News(10 mins):